Clinical trials: Schizophrenic Patients
Schizophrenia
A Study in Schizophrenic Patients
This study is designed to compare 3 doses of LY2140023 for the treatment of schizophrenia as assessed at endpoint (up to 7 weeks) using the Clinical Utility Index (CUI), a measure of efficacy, safety, and tolerability.
- Trial name
- NCT01125358
- Testing
- LY2140023
- Where
- 22 sites in Japan, South Korea and 1 more
- Volunteers
- 82 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
Schizophrenia Trial of Aripiprazole
Aripiprazole will show improved effectiveness over the standard of care treatment with one of three atypical antipsychotics (olanzapine, quetiapine and risperidone).
- Trial name
- NCT00237913
- Testing
- Aripiprazole, Olanzapine or Quetiapine or Risperidone
- Where
- 33 sites in Austria, Czechia and 7 more
- Volunteers
- 700 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Clozapine and Olanzapine Treatment of Aggression
This was a double-blind randomized study with three treatment arms: clozapine, olanzapine and haloperidol. We compared these three medications in the treatment of aggressive behavior over a 12 week period.
- Trial name
- NCT01123408
- Testing
- Clozapine, Olanzapine, Haloperidol
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia
Transcranial Direct Current Stimulation Influences on Cognitive Inhibition in Schizophrenia
A deficit in cognitive suppression is a trait of patients with schizophrenia. Cognitive suppression is the ability to control or suppress irrelevant responses and to adopt relevant responses instead.
- Trial name
- NCT01971073
- Testing
- transcranial direct current stimulation
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bar-Ilan University, Israel
Schizophrenia
Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients
The purpose of this study is to evaluate the effect of single doses of NSA-789 on the P50 component of the auditory evoked potentials and to assess the safety, tolerability and the concentration of NSA-789 in the blood, in…
- Trial name
- NCT00781794
- Testing
- NSA-789 at 2 different doses
- Where
- 3 sites in United States, France
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
Effect on Cognitive Function of a Treatment With Aripiprazole
To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.
- Trial name
- NCT00329810
- Testing
- Aripiprazole
- Volunteers
- 500 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.